Alps Group

Alps Group FCF/Debt

The Free Cash Flow to Debt Ratio of Alps Group (ALPS) as of Nov 4, 2026 is -45.87 %. In the previous year, Free Cash Flow to Debt Ratio was -79.81 % — a change of -42.52% (higher).

FCF/Debt

-45.87 %

YoY

-42.52%

Last updated:

Free Cash Flow to Debt Ratio of Alps Group is 2024 -45.87 % . Free Cash Flow to Debt Ratio of Alps Group was 2023 -79.81 % . It decreases by -42.52% higher compared to the previous year.

The Alps Group FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2023
-79.81 USD
Jan 1, 2024
-45.87 USD
The Alps Group FCF/Debt history
YEARFCF/DebtYoY
-45.87 %-42.52%
-79.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc generates revenue through its integrated biotechnology platform Alps Life Sciences Inc., which offers advanced therapies and healthcare solutions. The company provides medical services, wellness solutions, and aesthetic treatments including non-surgical and surgical aesthetic services. Alps Life Sciences Inc. develops and commercializes therapies such as MyImmune (NK cells), CAR-T cells, and diabetes therapeutics, alongside research in mRNA vaccine technology and stem cell advancements like iPSCs. The firm operates molecular and cGMP laboratories for research and cultivation of cell and gene therapies. Alps Group Inc. targets global healthcare providers and patients seeking advanced medical solutions. Its biotechnology pipeline covers diverse areas including cancer therapies, infectious disease treatments, and regenerative medicine. The company's integrated ecosystem combines research, development, medical services, and wellness solutions to improve healthcare outcomes. The firm's aesthetic services cater to individuals seeking cosmetic and wellness procedures, while its medical services address broader healthcare needs. The company's revenue streams include the sale of medical services, wellness solutions, and aesthetic treatments. Alps Life Sciences Inc. focuses on developing therapies for specific health conditions such as diabetes and cancer, with a pipeline that includes mRNA-based vaccines and cell therapies. The molecular and cGMP laboratories support the development and production of these advanced therapies, contributing to the company's product offerings. Alps Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alps Group stock

Free Cash Flow to Debt Ratio of Alps Group is -45.87 % in 2024.

Free Cash Flow to Debt Ratio of Alps Group changed from -79.81 % to -45.87 %, representing a -42.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Alps Group since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Alps Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Alps Group

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Alps Group